Previous 10 | Next 10 |
home / stock / hkmpy / hkmpy news
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals Canada NewsWire LONDON , April 29, 2022 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary ...
Update: Opiant Pharmaceuticals (NASDAQ:OPNT) has advised readers to disregard the news release issued via PR Newswire on Thursday about the purported licensing deal to market the company’s opioid overdose therapy OPNT003 in the EU and U.K. “This release contains incorrect inform...
Santa Monica, California-based Opiant Pharmaceuticals (NASDAQ:OPNT) has entered into a licensing deal with U.K.-based rival, Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) for OPNT003, an experimental therapy targeted at Opioid overdose, the companies announced on Friday. Per the terms of ...
Hikma Pharmaceuticals (OTCPK:HKMPF) (OTCPK:HKMPY) said it received preliminary approval from the U.S. Federal Trade Commission for its its acquisition of Custopharm from Water Street Healthcare Partners. The company said the parties have now obtained all regulatory approvals require...
Hikma Pharmaceuticals PLC (HKMPF) Q4 2021 Earnings Conference Call February 24, 2022 4:30 AM ET Company Participants Sigurdur Olafsson - Chief Executive Officer Khalid Nabilsi - Chief Financial Officer Conference Call Participants Emily Field - Barclays Bank Peter Verdult - Citigroup Thibault...
The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with their 2021 Q4 earnings call. For further details see: Hikma Pharmaceuticals PLC 2021 Q4 - Results - Earnings Call Presentation
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Despite the first months of the quarter favoring growth, ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy’s returns were relatively flat for th...
Suzhou Abogen Biosciences raised over $700 million in a record-breaking Series C round to support a Phase III trial of its mRNA COVID-19 vaccine. The company has completed a Phase II trial of the vaccine but hasn't released any data from the trial. BeyondSpring, a New York City-China ...
Bio-Thera Solutions and Hikma Pharmaceuticals (OTCPK:HKMPF) have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar to Jansen’s Stelara (ustekinumab), in U.S. Under the agreement, Bio-Thera will maintain ...
News, Short Squeeze, Breakout and More Instantly...
Hikma Pharmaceuticals Plc ADR Company Name:
HKMPY Stock Symbol:
OTCMKTS Market:
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Hikma Pharmaceuticals PLC (“Hikma”), a multinational pharmaceutical company, today announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screenin...
Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa PR Newswire SAN DIEGO , Aug. 10, 2023 /PRNewswire/ -- Rakuten Medical, Inc., a global biotechnology company devel...
Hikma expands impact in Canada with launches of new sterile injectable medicines Canada NewsWire Builds on company's growing position in Canadian sterile injectables market LONDON , March 9, 2023 /CNW/ -- Hikma Pharmaceuticals PLC (Hikma), the multination...